Cellule staminali: dal laboratorio alla clinica - Comtecmed.com

ePAPER READ

DOWNLOAD ePAPER

comtecmed.com

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

GIMEMA LAL1205 Protocol

Dasatinib

Dasatinib 70 mg twice a day (total planned treatment is 12

weeks, i.e. 84 days)

Diagnostic work-up (within 7 d) and immunophenotypic &

molecular monitoring of MRD carried out centrally in Rome

Bestellformular / Order Form 1/4 Veranstaltung ... - Comtecmed.com

GIMEMA LAL1205 Protocol Dasatinib Dasatinib 70 mg twice a day (total planned treatment is 12 weeks, i.e. 84 days) Diagnostic work-up (within 7 d) and immunophenotypic & molecular monitoring of MRD carried out centrally in Rome

GIMEMA LAL 1205 (Ph+ ALL) 55 patients enrolled 53 patients evaluable. Median age 53.6 years (range 23.8‐76.5) WBC (median) 18.8/mm 3 (range 2.2‐132.9) 33 p190, 20 p210 100% CHR 49 CHR (92.5%) already by day +22 No fatalities OS at 20 months 69.2% (median 30.8 months) DFS at 20 months 51.1% (median 21.1 months) Foà et al. ASH, EHA & BLOOD 2011

Page 1 and 2: CAN ALL BE MANAGED WITHOUT CHEMOTHE
Page 3: Enrolled: 45 patients Evaluable: 37
Page 7 and 8: GIMEMA LAL 0201‐B Overall surviva
Page 9 and 10: Incidence of molecular aberrations
Page 11 and 12: 331 genes GENE EXPRESSION PROFILE O
Page 13 and 14: Bispecific anti‐CD19/anti‐CD3
Page 15: CAN ALL BE MANAGED WITHOUT CHEMOTHE

Cellule staminali: dal laboratorio alla clinica - Comtecmed.com

Create successful ePaper yourself

Delete template?

Save as template?